^
Association details:
Biomarker:BCL2L1 mutation
Cancer:Triple Negative Breast Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer

Published date:
03/16/2023
Excerpt:
...univariate Cox regression analysis revealed that advanced TNBC patients with one of 12 mutant genes (CYP2D6 deletion and GNAS, BCL2L1, H3F3C, LAG3, FGF23, CCND2, SESN1, SNHG16, MYC, HLA-E, and MCL1 gain) had a shorter PFS with ICI treatment (p < 0.05)....Our data indicate that ICI efficacy in patients with advanced TNBC may be predicted by 12 mutant ctDNA genes.
DOI:
10.3389/fgene.2023.1125970